Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival

International Journal of Cancer

Volumn 137, Issue 3, 2015, Pages 638-645

  Yuan, Hua ^a,b,c   Liu, Hongliang ^a,b   Liu, Zhensheng ^a,b   Zhu, Dakai ^d   Amos, Christopher I ^d   Fang, Shenying ^e   Lee, Jeffrey E ^e   Wei, Qingyi ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NANJING MEDICAL UNIVERSITY   (China)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

cancer specific survival; Cox regression; cutaneous melanoma; Hippo pathway; single nucleotide polymorphisms

Indexed keywords

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; CUTANEOUS MELANOMA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC VARIABILITY; GERMLINE MUTATION; HIPPO SIGNALING PATHWAY; HUMAN; LATS1 GENE; LATS2 GENE; MAJOR CLINICAL STUDY; MALE; MOB1A GENE; MOB1B GENE; MST1 GENE; MST2 GENE; ONCOGENE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SAV1 GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TEAD1 GENE; TEAD2 GENE; TEAD3 GENE; TEAD4 GENE; YAP1 GENE; ADOLESCENT; AGED; ALLELE; CASE CONTROL STUDY; DNA METHYLATION; GENE EXPRESSION; GENETICS; GENOTYPE; MELANOMA; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY; YOUNG ADULT;

DNA BINDING PROTEIN; HIPPO PROTEIN, HUMAN; MUSCLE PROTEIN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TEAD1 PROTEIN, HUMAN; TEAD4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUSCLE PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; PHOSPHOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; ROC CURVE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84929514521     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29429     Document Type: Article

References (32)

1. Siegel R, Ma J, Zou Z, et al., Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. MacKie RM, Hauschild A, Eggermont AM,. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009; 20 (Suppl 6): vi1-vi7.
3. Chapman PB, Hauschild A, Robert C, et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
4. Young K, Minchom A, Larkin J., BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future Oncol 2012; 8: 499-507.
5. Weinstein D, Leininger J, Hamby C, et al., Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol 2014; 7: 13-24.
6. Balch CM, Gershenwald JE, Soong SJ, et al., Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
7. Schramm SJ, Mann GJ., Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther 2011; 10: 1520-8.
8. Rachakonda PS, Hosen I, de Verdier PJ, et al., TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA 2013; 110: 17426-31.
9. Costa BM, Viana-Pereira M, Fernandes R, et al., Impact of EGFR genetic variants on glioma risk and patient outcome. Cancer Epidemiol Biomarkers Prev 2011; 20: 2610-17.
10. Li C, Yin M, Wang LE, et al., Polymorphisms of nucleotide excision repair genes predict melanoma survival. J Invest Dermatol 2013; 133: 1813-21.
11. Edgar BA,. From cell structure to transcription: Hippo forges a new path. Cell 2006; 124: 267-73.
12. Kim JE, Finlay GJ, Baguley BC., The role of the hippo pathway in melanocytes and melanoma. Front Oncol 2013; 3: 123.
13. Harvey KF, Zhang X, Thomas DM., The Hippo pathway and human cancer. Nat Rev Cancer 2013; 13: 246-57.
14. Dong J, Feldmann G, Huang J, et al., Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130: 1120-33.
15. Nallet-Staub F, Marsaud V, Li L, et al., Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol 2014; 134: 123-32.
16. Amos CI, Wang LE, Lee JE, et al., Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet 2011; 20: 5012-23.
17. Yin J, Liu H, Liu Z, et al., Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival. J Invest Dermatol 2015; 135: 542-50.
18. Gershenwald JE, Ross MI., Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 2011; 364: 1738-45.
19. Chan SW, Lim CJ, Chen L, et al., The Hippo pathway in biological control and cancer development. J Cell Physiol 2011; 226: 928-39.
20. Wacholder S, Chanock S, Garcia-Closas M, et al., Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-42.
21. Aulchenko YS, Ripke S, Isaacs A, et al., GenABEL: an R library for genome-wide association analysis. Bioinformatics 2007; 23: 1294-6.
22. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
23. Holm K, Melum E, Franke A, et al., SNPexp-a web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels. BMC Bioinformatics 2010; 11: 600.
24. Grundberg E, Small KS, Hedman AK, et al., Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet 2012; 44: 1084-9.
25. Grundberg E, Meduri E, Sandling JK, et al., Global analysis of DNA methylation variation in adipose tissue from twins reveals links to disease-associated variants in distal regulatory elements. Am J Hum Genet 2013; 93: 876-90.
26. Lamar JM, Stern P, Liu H, et al., The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA 2012; 109: E2441-E2450.
27. Overholtzer M, Zhang J, Smolen GA, et al., Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006; 103: 12405-10.
28. Lin XY, Zhang XP, Wu JH, et al., Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer. Tumour Biol 2014; 35: 6435-43.
29. Xia Y, Chang T, Wang Y, et al., YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PloS One 2014; 9: e91770.
30. Wu C, Xu BH, Yuan P, et al., Genome-Wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients. Cancer Res 2010; 70: 9721-9.
31. Hu X, Xin Y, Xiao Y, et al., Overexpression of YAP1 is correlated with progression, metastasis and poor prognosis in patients with gastric carcinoma. Pathol Oncol Res 2014; 20: 805-11.
32. Knight JF, Shepherd CJ, Rizzo S, et al., TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer 2008; 99: 1849-58.